ZOMETA® Case Study | ZOMETA Can Delay And Reduce SREs In Patients With Renal Cell Carcinoma
Home

Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
ZOMETA Patient Case Study: Renal Cell Carcinoma ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Renal Cell Carcinoma Patient Case Study – Carlo Carlo V.
  • Aged 67 years
  • Retired accountant
  • Takes sculpting classes twice a week
Medical Profile The clinical question Reasons for ZOMETA How to use ZOMETA References
Page  1 2 3

ZOMETA® can delay and reduce SREs in patients like Carlo with advanced renal cell carcinoma

Efficacy of ZOMETA vs placebo in patients with advanced renal cell carcinoma2
Efficacy of ZOMETA vs placebo in patients with advanced renal cell carcinoma graph
NR=not reached.


  • ZOMETA significantly extended time to first SRE vs placebo (median not reached
    vs 72 days, P=.006)2
  • ZOMETA reduced the percentage of patients who experienced an SRE by half vs placebo(37% vs 74%, P=.015)2

ZOMETA can delay and reduce SREs in patients like Carlo with renal cell carcinoma and bone metastases2


Page  1 2 3


 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologySiteMapContactPrivacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.